Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2643454 | 0.85 | ALDH1A1 (0.34) | ALDH1A1KMT2AMEN1 | |
| SCHEMBL2644120 | 0.82 | RORC (0.36) | ALDH1A1 | |
| SCHEMBL2643619 | 0.78 | ALDH1A1 (0.42) | CYP2C19CYP2C9ALDH1A1CA12CA1 | |
| SCHEMBL2643582 | 0.72 | MAPT (0.40) | CYP2C19CYP2C9ALDH1A1CA12CA1 | |
| SCHEMBL2664915 | 0.70 | CASP3 (0.39) | CYP2C19CYP2C9ALDH1A1CA12CA1 | |
| SCHEMBL2664954 | 0.70 | CASP3 (0.39) | CYP2C19CYP2C9ALDH1A1CA12CA1 | |
| SCHEMBL2644689 | 0.70 | MAPT (0.43) | CYP2C19CYP2C9ALDH1A1KMT2APOLB | |
| SCHEMBL2644254 | 0.68 | MEN1 (0.50) | CYP2C19CYP2C9ALDH1A1MDM2KMT2A | |
| SCHEMBL31667491 | 0.67 | CYP2C9 (0.65) | CYP2C19CYP2C9ALDH1A1CA12CA1 | |
| SCHEMBL2644952 | 0.67 | MAPT (0.36) | MDM2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796313-B2 | Substituted dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-08-05 | — | — | US | disclosed |
| CN-101316836-A | Substituted dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA NV (BE) | 2008-12-03 | — | — | CN | disclosed |
| US-20070099930-A1 | Substituted Dihydroisoindolones As Allosteric Modulators of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099930-A1 | Substituted Dihydroisoindolones As Allosteric Modulators of Glucokinase | GCK, GCKR, GPR119 | CYP2C19 1213/4885CYP2C9 1845/4885ALDH1A1 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.